Cell-Free DNA Testing Transplant Market

Kidney transplant leads the cell-free DNA testing transplant market with a 31.7% share in 2026 by transplant type, followed by acute rejection monitoring at 36.8% by application and next-generation sequencing at 36.5% by technology. Adoption reflects demand for non-invasive graft monitoring, while testing costs and clinical validation requirements remain key constraints.